
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen is a growing medical technology company, with a solid product portfolio of diagnostic testing products that are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases. The company has a strong track record of revenue growth and profitability, and we expect this trend to continue in the future, driven by market demand for its innovative products and ongoing investments in R&D and sales expansion. Additionally, the company has a focused strategy to increase its ASP and expand its test volume, which we believe will support its long-term growth potential. Despite some near-term headwinds, we believe Exagen's shares are currently undervalued and continue to recommend a BUY rating with a price target of $10.
Bears say
Exagen is facing significant risks in the form of third-party reimbursement issues and limited free cash flow, which are affecting its financial performance and peer valuation. Additionally, the company's reliance on a single operating segment and facility poses operational risks. This, combined with outstanding debt and the potential need for additional capital, leads to a negative outlook on Exagen's stock.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares